新药奥贝胆酸治疗非酒精性脂肪性肝病进展
The Treatment Progression of Obeticholic Acid in Non-Alcoholic Fatty Liver Disease
DOI: 10.12677/ACM.2022.12121643, PDF,   
作者: 董方园：济宁医学院临床医学院，山东 济宁；孔令斌*：济宁医学院，山东 济宁
关键词: 奥贝胆酸；非酒精性脂肪肝性肝病；非酒精性脂肪性肝炎；Obeticholic Acid； Non-Alcoholic Fatty Liver Disease； Non-Alcoholic Steatohepatitis
摘要: 随着全球肥胖症的流行，非酒精性脂肪性肝病发病率逐年上升，给世界造成了极大的临床与经济负担，也严重危害了公共健康。但迄今为止没有批准的治疗非酒精性脂肪性肝病的特异性药物。目前，只有一款新药奥贝胆酸正处于基于组织学研究的大型临床3期试验中。最新研究发现，奥贝胆酸展现出了优越的治疗效果，可以显著改善脂肪肝患者的肝纤维化程度，但该药物也表现出了一定的副作用，现就奥贝胆酸治疗非酒精性脂肪性肝病的现状综述如下。
Abstract: With the global epidemic of obesity, the incidence of non-alcoholic fatty liver disease is increasing year by year, bringing a huge clinical and economic burden to the world and seriously endangering public health. So far, there are no approved specific drugs for the treatment of non-alcoholic fatty liver disease. At present, only a new drug called Obeticholic acid is in a large clinical phase 3 trial based on histological research. The latest research found that Obeticholic acid showed superior treatment effect, which can significantly improve the degree of liver fibrosis in fatty liver patients. But, the drug also showed certain side effects. The current status of Obeticholic acid for non-alcoholic fatty liver disease is reviewed as follows.
文章引用：董方园, 孔令斌. 新药奥贝胆酸治疗非酒精性脂肪性肝病进展[J]. 临床医学进展, 2022, 12(12): 11399-11404. https://doi.org/10.12677/ACM.2022.12121643

参考文献

[1] Younossi, Z.M., Koenig, A.B., Abdelatif, D., et al. (2016) Global Epidemiology of Nonalcoholic Fatty Liver Dis-ease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes. Hepatology (Baltimore, Md.), 64, 73-84. [Google Scholar] [CrossRef] [PubMed]
[2] Younossi, Z.M., Ratziu, V., Loomba, R., et al. (2019) Obeticholic Acid for the Treatment of Non-Alcoholic Steatohepatitis: Interim Analysis from a Multicentre, Randomised, Placebo-Controlled Phase 3 Trial. The Lancet, 394, 2184-2196.
[3] Buzzetti, E., Pinzani, M. and Tsochatzis, E.A. (2016) The Multiple-Hit Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD). Metabolism: Clinical and Experimental, 65, 1038-1048. [Google Scholar] [CrossRef] [PubMed]
[4] Goldberg, D., Ditah, I.C., Saeian, K., et al. (2017) Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease among Patients with Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. Gastroenterology, 152, 1090-1099. [Google Scholar] [CrossRef] [PubMed]
[5] Younossi, Z., Anstee, Q.M., Marietti, M., et al. (2018) Global Burden of NAFLD and NASH: Trends, Predictions, Risk Factors and Prevention. Nature Reviews. Gastroenterology & Hepatology, 15, 11-20. [Google Scholar] [CrossRef] [PubMed]
[6] Ye, Q., Zou, B., Yeo, Y.H., et al. (2020) Global Prevalence, Inci-dence, and Outcomes of Non-Obese or Lean Non-Alcoholic Fatty Liver Disease: A Systematic Review and Me-ta-Analysis. The Lancet. Gastroenterology & Hepatology, 5, 739-752. [Google Scholar] [CrossRef] 
[7] Ratziu, V. (2018) A Critical Review of Endpoints for Non-Cirrhotic NASH Therapeutic Trials. Journal of Hepatology, 68, 353-361. [Google Scholar] [CrossRef] [PubMed]
[8] Kremoser, C. (2021) FXR Agonists for NASH: How Are They Different and What Difference Do They Make? Journal of Hepatology, 75, 12-15. [Google Scholar] [CrossRef] [PubMed]
[9] Cobbina, E. and Akhlaghi, F. (2017) Non-Alcoholic Fatty Liver Disease (NAFLD)—Pathogenesis, Classification, and Effect on Drug Metabolizing Enzymes and Transporters. Drug Metabolism Reviews, 49, 197-211. [Google Scholar] [CrossRef] [PubMed]
[10] Friedman, S.L., Neuschwander-Tetri, B.A., Rinella, M., et al. (2018) Mechanisms of NAFLD Development and Therapeutic Strategies. Nature Medicine, 24, 908-922. [Google Scholar] [CrossRef] [PubMed]
[11] Attia, S.L., Softic, S. and Mouzaki, M. (2021) Evolving Role for Pharmacotherapy in NAFLD/NASH. Clinical and Translational Science, 14, 11-19. [Google Scholar] [CrossRef] [PubMed]
[12] Chow, M.D., Lee, Y. and Guo, G.L. (2017) The Role of Bile Acids in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Molecular Aspects of Medicine, 56, 34-44. [Google Scholar] [CrossRef] [PubMed]
[13] Guo, C., LaCerte, C., Edwards, J.E., et al. (2018) Farnesoid X Receptor Agonists Obeticholic Acid and Chenodeoxycholic Acid Increase Bile Acid Efflux in Sandwich-Cultured Human Hepatocytes: Functional Evidence and Mechanisms. The Journal of Pharmacology and Experimental Thera-peutics, 365, 413-421. [Google Scholar] [CrossRef] [PubMed]
[14] Adorini, L., Pruzanski, M. and Shapiro, D. (2012) Farnesoid X Re-ceptor Targeting to Treat Nonalcoholic Steatohepatitis. Drug Discovery Today, 17, 988-997. [Google Scholar] [CrossRef] [PubMed]
[15] Cariou, B., van Harmelen, K., Duran-Sandoval, D., et al. (2006) The Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice. The Journal of Biological Chemistry, 281, 11039-11049. [Google Scholar] [CrossRef] 
[16] Ma, K., Saha, P.K., Chan, L., et al. (2006) Farnesoid X Receptor Is Essential for Normal Glucose Homeostasis. Journal of Clinical Investigation, 116, 1102-1109. [Google Scholar] [CrossRef] 
[17] Zhang, Y., Lee, F.Y., Barrera, G., et al. (2006) Activation of the Nuclear Receptor FXR Improves Hyperglycemia and Hyperlipidemia in Diabetic Mice. Proceedings of the National Academy of Sciences of the United States of America, 103, 1006-1011. [Google Scholar] [CrossRef] [PubMed]
[18] Rizzo, G., Disante, M., Mencarelli, A., et al. (2006) The Farnesoid X Receptor Promotes Adipocyte Differentiation and Regulates Adipose Cell Function in Vivo. Molecular Pharmacology, 70, 1164-1173. [Google Scholar] [CrossRef] [PubMed]
[19] Hollman, D.A.A., Milona, A., van Erpecum, K.J., et al. (2012) An-ti-Inflammatory and Metabolic Actions of FXR: Insights into Molecular Mechanisms. Biochimica et Biophysica Acta, 1821, 1443-1452. [Google Scholar] [CrossRef] [PubMed]
[20] Trauner, M., Fuchs, C.D., Halilbasic, E., et al. (2017) New Therapeutic Concepts in Bile Acid Transport and Signaling for Management of Cholestasis. Hepatology (Baltimore, Md.), 65, 1393-1404. [Google Scholar] [CrossRef] [PubMed]
[21] Jhaveri, M.A. and Kowdley, K.V. (2017) New De-velopments in the Treatment of Primary Biliary Cholangitis—Role of Obeticholic Acid. Therapeutics and Clinical Risk Management, 13, 1053-1060. [Google Scholar] [CrossRef] 
[22] Song, K., Li, T., Owsley, E., et al. (2009) Bile Acids Activate Fi-broblast Growth Factor 19 Signaling in Human Hepatocytes to Inhibit Cholesterol 7alpha-Hydroxylase Gene Expression. Hepatology (Baltimore, Md.), 49, 297-305. [Google Scholar] [CrossRef] [PubMed]
[23] Kir, S., Beddow, S.A., Samuel, V.T., et al. (2011) FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis. Science (New York, N.Y.), 331, 1621-1624. [Google Scholar] [CrossRef] [PubMed]
[24] Manne, V. and Kowdley, K.V. (2019) Obeticholic Acid in Primary Biliary Cholangitis: Where We Stand. Current Opinion in Gastroenterology, 35, 191-196. [Google Scholar] [CrossRef] 
[25] Larter, C.Z., Chitturi, S., Heydet, D., et al. (2010) A Fresh Look at NASH Pathogenesis. Part 1: The Metabolic Movers. Journal of Gastroenterology and Hepatology, 25, 672-690. [Google Scholar] [CrossRef] [PubMed]
[26] Mudaliar, S., Henry, R.R., Sanyal, A.J., et al. (2013) Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. Gastroenterology, 145, 574-582. [Google Scholar] [CrossRef] [PubMed]
[27] Neuschwander-Tetri, B.A., Loomba, R., Sanyal, A.J., et al. (2015) Farnesoid X Nuclear Receptor Ligand Obeticholic Acid for Non-Cirrhotic, Non-Alcoholic Steatohepatitis (FLINT): A Multicentre, Randomised, Placebo-Controlled Trial. The Lancet (London, England), 385, 956-965. [Google Scholar] [CrossRef] 
[28] Pockros, P.J., Fuchs, M., Freilich, B., et al. (2019) CONTROL: A Randomized Phase 2 Study of Obeticholic Acid and Atorvastatin on Lipoproteins in Nonalcoholic Steatohepatitis Patients. Liver International, 39, 2082-2093. [Google Scholar] [CrossRef] [PubMed]
[29] Al-Dury, S., Wahlström, A., Panzitt, K., et al. (2019) Obeticholic Acid May Increase the Risk of Gallstone Formation in Susceptible Patients. Journal of Hepatology, 71, 986-991. [Google Scholar] [CrossRef] [PubMed]
[30] Mullard, A. (2020) FDA Rejects NASH Drug. Nature Reviews Drug Discovery, 19, 501. [Google Scholar] [CrossRef] [PubMed]

为你推荐